The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.

In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.

A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.

In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg vs placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.

As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.

A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.